Pluri (FRA:4DX) FFO


FRA:4DX Pluri Inc FRA:4DX
25 GF Score
Price €5.60
GF Value €17.09
! 6 Warning Signs
View Full Analysis

What is Pluri FFO?

FFO (Funds from operations) only applies to REITs.

FRA:4DX
25GF Score
Pluri Inc FRA:4DX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pluri (FRA:4DX) Overvalued in 2026?

Based on GuruFocus' analysis, Pluri stock appears to be undervalued. The current stock price of €5.60 is trading 67.2% below its estimated GF Value™ of €17.09.

Key valuation signals for FRA:4DX:

  • FFO:
  • GF Value™: €17.09 vs. price of €5.60 (67.2% below fair value)
  • GF Score™: 25/100 with 6 warning signs

No single metric tells the full story. See the FRA:4DX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pluri Business Description

Other Exchanges PLUR:USAPLUR:Israel
Address MATAM Advanced Technology Park, Building No. 5, Haifa, ISR, 3508409
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
25GF Score

Get the complete analysis for FRA:4DX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.60
Price
€17.09
GF Value